Fosamax (alendronate) to be promoted to PREVENT osteoporosis
April 1997
The FDA will soon allow Fosamax (alendronate) to be promoted to PREVENT osteoporosis. It was originally approved for treatment.
Fosamax slows bone loss and increases bone density. It reduces hip fractures by 50% in women who already have osteoporosis.
Now it'll also be used for women who are at risk because of early menopause...thin build...Caucasian or Asian race...family history...or a low bone density.
Upgrade now to access this resource
This content is not available under the subscriptions purchased by your organization, but you can add it on!
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.